
Collage photo of Michael Milano and Martin Tom/X
Aug 16, 2024, 19:37
Shearwood McClelland III: Financial Toxicity associated with achieving PFS based on the INDIGO trial
Shearwood McClelland III, Director of Spine Oncology, Department of Radiation Oncology at University Hospitals, shared a post on X about his recent paper, commenting:
“Pleased to publish our piece regarding the Financial Toxicity associated with achieving progression-free survival based on the INDIGO trial with Michael Milano and Martin Tom!”
The Cost of Progression-Free Survival in Treating Low-Grade Glioma published in American Journal of Clinical Oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 12:41
Feb 21, 2025, 12:39
Feb 21, 2025, 11:36
Feb 21, 2025, 11:29
Feb 21, 2025, 10:45